Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24568764 | 0.90 | CYP11B1 (0.43) | CYP11B1CYP11B2CHRNB2CHRNA4RIPK2 | |
| SCHEMBL12500664 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL5849238 | 0.84 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL23059886 | 0.84 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL5851052 | 0.83 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL17593809 | 0.80 | IKBKB (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL12104597 | 0.80 | SYK (0.42) | CYP11B1CYP11B2CHRNB2CHRNA4RIPK2 | |
| Hydrochloric Acid SCHEMBL15206028 | 0.79 | IKBKB (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL15206156 | 0.78 | CHRNB2 (0.50) | CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL16217387 | 0.76 | CNR2 (0.39) | CYP11B1CYP11B2CHRNB2CHRNA4RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085395-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | Targacept, Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2896619-A1 | Salt forms of (R)-3-(E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE AND their USE | Targacept, Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2896619-A1 | Salt forms of (R)-3-(E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE AND their USE | Targacept, Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20150164894-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20140107163-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE | Targecept, Inc. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107164-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107163-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE | Targecept, Inc. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107163-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE | Targecept, Inc. (US) | 2014-04-17 | — | — | US | disclosed |
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7098331-B2 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060094732-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | SCHMITT JEFFREY D | 2006-05-04 | — | — | US | disclosed |
| EP-1601670-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | Targacept Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | DULL GARY M | 2005-12-01 | — | — | US | disclosed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2004078752-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176348-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | AVENTIS PHARMA S.A. | 2004-09-09 | — | — | US | disclosed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176348-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | CHRNA5, OPRK1, CHRNA6 | CYP11B1 307/4885CYP11B2 333/4885CHRNB2 7/4885 |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | CYP11B1 225/4885CYP11B2 169/4885CHRNB2 723/4885 |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | CYP11B1 225/4885CYP11B2 169/4885CHRNB2 723/4885 |
| US-20060094732-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | CHRNA5, OPRK1, CHRNA6 | CYP11B1 307/4885CYP11B2 333/4885CHRNB2 7/4885 |
| US-20140107164-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | CHRNA5, OPRK1, CHRNA6 | CYP11B1 307/4885CYP11B2 333/4885CHRNB2 7/4885 |
| US-20140107163-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, REN, SRMS | CYP11B1 1866/4885CYP11B2 1371/4885CHRNB2 4372/4885 |
| US-20150164894-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | CHRNA5, OPRK1, CHRNA6 | CYP11B1 307/4885CYP11B2 333/4885CHRNB2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.